Comparative Analysis of IL-18 Expression Across Therapeutic Modalities in Multiple Sclerosis

Background

Multiple sclerosis represents a chronic autoimmune pathology associated with immune-related demyelination and neuro inflammation in the central nervous system. Recently, interleukin-18 appears to represent one of the major cytokines among other inflammatory mediators, responsible for innate and adaptive immunity cross-talk and involvement in disease development. Its behavior in diverse therapeutic regimes remains not sufficiently studied.